Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
Summary
Funding supports the commercial product development of VisioLite\xae Device and Laser Scleral Microporation Human Clinical Study.Capital raised to date provides strong financial position to prepare the device for regulatory trials and submissions.BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc, (AVG or the Company) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.The new capital will support the continued development of the companys proprietary Gen II VisioLite\xae Ophthalmic Laser, which delivers the minimally invasive LSM procedure a treatment targeting the loss of Dynamic Range of Focus caused by presbyopia.This Series B funding marks a critical inflection point for our company, said Dr. AnnMarie Hipsley, founder and CEO of Ace Vision Group. We remain on track to submit our 510(k) application in 2026.The investment round was led by a syndicate of prominent eye care investors, underscoring strong market validation for a safe, office-based procedure that addresses the underlying biomechanical cause of presbyopia. In a recent pilot study using a Gen I device, the procedure showed encouraging outcomes, with a majority of patients no longer requiring reading glasses after treatment. This level of market relatability, combined with strong clinical interest and favorable economics, positions us for broad adoption and long-term value creation, added Dr. Hipsley.Ace Vision Group, Inc. (AVG) is a privately held U.S. ophthalmic medical device company developing Laser Microporation Therapeutic technologies to address age-related eye dysfunction and address the eyes natural biomechanical performance. AVGs brand promise is to provide the field of ophthalmology with innovative devices, Microporation Therapeutic procedures, and education for the treatment of age-related ocular dysfunction, disability, and disease.